<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242385</url>
  </required_header>
  <id_info>
    <org_study_id>460501</org_study_id>
    <nct_id>NCT00242385</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of ARALAST (Human Alpha1- PI)</brief_title>
  <official_title>Single-Dose, Double-Blind, Crossover Study to Evaluate the Pharmacokinetic Comparability of ARALAST Fraction IV-1 Alpha1-Proteinase Inhibitor (ARALAST Fr. IV-1) and ARALAST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to characterize the pharmacokinetic profile of
      intravenous Aralast Fraction (Fr.) IV-1, a sterile, stable, lyophilized preparation of
      functionally intact human Alpha1- Proteinase Inhibitor (α1-PI). This pharmacokinetic study
      will be a randomized controlled clinical trial with a cross-over design. Twenty-four subjects
      will be enrolled into the study. Overall study duration will be approximately 6-8 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve/Dose</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Area under the plasma alpha1-proteinase inhibitor (α1-PI) concentration versus time curve (AUC) calculated by linear trapezoidal method per dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Area Under the Curve Per Dose</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Total area under the α1-PI concentration vs. time curve from pharmacokinetic day 0 to time infinity (AUC 0-infinity) per dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL)</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Computed as dose divided by AUC 0-infinity (AUC 0-infinity was calculated as the sum of AUC from time 0 to the time of last quantifiable concentration plus a tail area correction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Computed as total area under the moment curve (AUMC) divided by total AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady State</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Computed as weight-adjusted CL * MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Computed from the terminal or disposition rate constant obtained from log_e -linear fitting using the least squares deviation to the last five quantifiable concentrations above pre-infusion level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Maximum α1-PI concentration following infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum α1-PI Concentration Post-infusion (Tmax)</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Time to reach C-max. Tmax is the number of days from infusion to maximum concentration. Samples drawn at the end of infusion are considered to be time zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery</measure>
    <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
    <description>Computed from Cmax (mg/ml) divided by dose per kg body weight (mg/kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Throughout study period (7 months)</time_frame>
    <description>Investigators assessed severity of AEs (occurring during or after infusions) based on:
MILD: Transient discomfort, does not interfere in a significant manner with participant's normal functioning level; Resolves spontaneously or may require minimal therapeutic intervention MODERATE: AE produces limited impairment of function, can require therapeutic intervention; AE produces no sequelae; SEVERE: AE results in marked impairment of function, can lead to temporary inability to resume usual life pattern; AE produces sequelae, which require prolonged therapeutic intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>ARALAST Fr. IV-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARALAST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor</intervention_name>
    <description>Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.</description>
    <arm_group_label>ARALAST Fr. IV-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dose of 60 mg/kg alpha1-proteinase inhibitor</intervention_name>
    <description>Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.</description>
    <arm_group_label>ARALAST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject or subject´s legally authorized representative has provided written
             informed consent

          -  Subject is 18 years of age or older

          -  Subject has a documented, endogenous plasma Alpha1-PI level &lt; 8 Micromolar

          -  Subject is of the genotype Pi*Z/Z, Pi*Z/Null, Pi*Null/Null, Pi*Malton/Z, or others,
             dependent on the approval by the Sponsor

          -  If the subject is female or of childbearing potential, the subject has a negative
             urine test for pregnancy within 7 days prior to first study product administration and
             agrees to employ adequate birth control measures for the duration of the study

          -  Laboratory results obtained at the screening visit, meeting the following criteria:

               -  Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) &lt;= 2 times
                  the upper limit of normal (ULN)

               -  Serum total bilirubin &lt;= 2 times ULN

               -  Proteinuria &lt; +2 on dipstick analysis

               -  Serum creatinine &lt;= 1.5 times ULN

               -  Absolute neutrophil count (ANC) &gt;= 1500 cells/mm3

               -  Hemoglobin &gt;= 10.0 g/dL

               -  Platelet count &gt;= 10^5/mm3

          -  If the subject is treated with any respiratory medications, including inhaled
             bronchodilators and inhaled or oral corticosteroids, the subjects´ medication doses
             were unchanged for at least 14 days prior to first study product administration

          -  Nonsmoker for a minimum of 3 months prior to first study product administration

        Exclusion Criteria:

          -  The subject has received any Alpha1-PI augmentation therapy (including Aralast and
             investigational Alpha1-PIs, by any route including intravenous and inhaled) within 42
             days prior to first study product administration

          -  The subject has received an investigational drug or device within 1 month prior to
             first study product administration, or the subject is currently receiving an
             investigational drug

          -  The subject has a known selective immunoglobulin A (IgA) deficiency (IgA level &lt; 15
             mg/dL) and/or antibody to IgA

          -  The subject has a pulmonary exacerbation or had a pulmonary exacerbation in the past
             14 days prior to first study product administration

          -  The subject is pregnant or lactating, or intends to become pregnant during the course
             of the study

          -  The subject has a clinically significant medical, psychiatric, or cognitive illness,
             or recreational drug/alcohol use that, in the opinion of the investigator, would
             affect subject safety or compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Garrett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Middlemore Hospital, Otahuhu, Auckland, New Zealand</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otahuhu</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2005</study_first_submitted>
  <study_first_submitted_qc>October 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2005</study_first_posted>
  <results_first_submitted>February 15, 2011</results_first_submitted>
  <results_first_submitted_qc>July 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2011</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <name_title>David Gelmont, MD, Global Medical Director, Head of Specialty Products TA, BioTherapeutics</name_title>
    <organization>Baxter Healthcare Corporation</organization>
  </responsible_party>
  <keyword>Severe congenital Alpha1-Proteinase Inhibitor (Alpha1-PI) deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted at seven clinical sites in Australia (4 sites) and New Zealand (3 sites) beginning in December 2005.</recruitment_details>
      <pre_assignment_details>All 25 enrolled subjects were assigned to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ARALAST Fr. IV-1 Then Aralast</title>
          <description>Subjects were randomized to receive either single dose ARALAST 60 mg/kg or single-dose ARALAST Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.</description>
        </group>
        <group group_id="P2">
          <title>ARALAST Then ARALAST Fr. IV-1</title>
          <description>Subjects were randomized to receive either single dose ARALAST 60 mg/kg or single-dose ARALAST Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Severe Congenital α1-PI Deficiency</title>
          <description>Subjects were randomized to receive either single dose ARALAST 60 mg/kg or single-dose ARALAST Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="20" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve/Dose</title>
        <description>Area under the plasma alpha1-proteinase inhibitor (α1-PI) concentration versus time curve (AUC) calculated by linear trapezoidal method per dose.</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>All study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve/Dose</title>
          <description>Area under the plasma alpha1-proteinase inhibitor (α1-PI) concentration versus time curve (AUC) calculated by linear trapezoidal method per dose.</description>
          <population>All study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>days*kg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0822" lower_limit="0.0750" upper_limit="0.094"/>
                    <measurement group_id="O2" value="0.0920" lower_limit="0.0804" upper_limit="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish bioequivalence in AUC 0-35d divided by the dose administered with a type I error of 5% the calculated two-sided 90% confidence interval were to be contained completely in the margins of equivalence defined as 80% to 125%.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.928</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.858</ci_lower_limit>
            <ci_upper_limit>1.002</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Area Under the Curve Per Dose</title>
        <description>Total area under the α1-PI concentration vs. time curve from pharmacokinetic day 0 to time infinity (AUC 0-infinity) per dose</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Total Area Under the Curve Per Dose</title>
          <description>Total area under the α1-PI concentration vs. time curve from pharmacokinetic day 0 to time infinity (AUC 0-infinity) per dose</description>
          <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>days*kg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0825" lower_limit="0.0750" upper_limit="0.095"/>
                    <measurement group_id="O2" value="0.0928" lower_limit="0.0812" upper_limit="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish bioequivalence in AUC 0-infinity divided by the dose administered with a type I error of 5% the calculated two-sided 90% confidence interval were to be contained completely in the margins of equivalence defined as 80% to 125%.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.934</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.855</ci_lower_limit>
            <ci_upper_limit>1.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (CL)</title>
        <description>Computed as dose divided by AUC 0-infinity (AUC 0-infinity was calculated as the sum of AUC from time 0 to the time of last quantifiable concentration plus a tail area correction)</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (CL)</title>
          <description>Computed as dose divided by AUC 0-infinity (AUC 0-infinity was calculated as the sum of AUC from time 0 to the time of last quantifiable concentration plus a tail area correction)</description>
          <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>mL/day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="951" lower_limit="782" upper_limit="1115"/>
                    <measurement group_id="O2" value="856" lower_limit="782" upper_limit="918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT)</title>
        <description>Computed as total area under the moment curve (AUMC) divided by total AUC</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT)</title>
          <description>Computed as total area under the moment curve (AUMC) divided by total AUC</description>
          <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="3.9" lower_limit="4.5" upper_limit="7.8"/>
                    <measurement group_id="O2" value="6.9" spread="2.8" lower_limit="5.8" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution at Steady State</title>
        <description>Computed as weight-adjusted CL * MRT</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution at Steady State</title>
          <description>Computed as weight-adjusted CL * MRT</description>
          <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5606" lower_limit="4624" upper_limit="6162"/>
                    <measurement group_id="O2" value="5405" lower_limit="4454" upper_limit="6703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life</title>
        <description>Computed from the terminal or disposition rate constant obtained from log_e -linear fitting using the least squares deviation to the last five quantifiable concentrations above pre-infusion level.</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life</title>
          <description>Computed from the terminal or disposition rate constant obtained from log_e -linear fitting using the least squares deviation to the last five quantifiable concentrations above pre-infusion level.</description>
          <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.1" upper_limit="5.4"/>
                    <measurement group_id="O2" value="4.2" lower_limit="4.0" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <description>Maximum α1-PI concentration following infusion</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <description>Maximum α1-PI concentration following infusion</description>
          <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>mg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.5" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum α1-PI Concentration Post-infusion (Tmax)</title>
        <description>Time to reach C-max. Tmax is the number of days from infusion to maximum concentration. Samples drawn at the end of infusion are considered to be time zero.</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum α1-PI Concentration Post-infusion (Tmax)</title>
          <description>Time to reach C-max. Tmax is the number of days from infusion to maximum concentration. Samples drawn at the end of infusion are considered to be time zero.</description>
          <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery</title>
        <description>Computed from Cmax (mg/ml) divided by dose per kg body weight (mg/kg).</description>
        <time_frame>Pharmacokinetic evaluation: 30 minutes pre-infusion up to 35 days post-infusion</time_frame>
        <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery</title>
          <description>Computed from Cmax (mg/ml) divided by dose per kg body weight (mg/kg).</description>
          <population>Full Analysis Data Set - all study subjects who received at least 1 dose of study product, and provided data suitable for pharmacokinetic analysis</population>
          <units>(mg/mL) / (mg/kg)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0259" lower_limit="0.0234" upper_limit="0.028"/>
                    <measurement group_id="O2" value="0.0258" lower_limit="0.0237" upper_limit="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AEs)</title>
        <description>Investigators assessed severity of AEs (occurring during or after infusions) based on:
MILD: Transient discomfort, does not interfere in a significant manner with participant’s normal functioning level; Resolves spontaneously or may require minimal therapeutic intervention MODERATE: AE produces limited impairment of function, can require therapeutic intervention; AE produces no sequelae; SEVERE: AE results in marked impairment of function, can lead to temporary inability to resume usual life pattern; AE produces sequelae, which require prolonged therapeutic intervention</description>
        <time_frame>Throughout study period (7 months)</time_frame>
        <population>Safety Analysis Data Set - all study subjects who had evidence of receiving at least one dose of study medication regardless of any protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>ARALAST Fr. IV-1</title>
            <description>Single-dose ARALAST Fr. IV-1 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
          <group group_id="O2">
            <title>ARALAST</title>
            <description>Single dose ARALAST 60 mg/kg administered at 0.2 mL/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs)</title>
          <description>Investigators assessed severity of AEs (occurring during or after infusions) based on:
MILD: Transient discomfort, does not interfere in a significant manner with participant’s normal functioning level; Resolves spontaneously or may require minimal therapeutic intervention MODERATE: AE produces limited impairment of function, can require therapeutic intervention; AE produces no sequelae; SEVERE: AE results in marked impairment of function, can lead to temporary inability to resume usual life pattern; AE produces sequelae, which require prolonged therapeutic intervention</description>
          <population>Safety Analysis Data Set - all study subjects who had evidence of receiving at least one dose of study medication regardless of any protocol violation.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious AEs - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious AEs - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious AEs - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire study period (7 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ARALAST Fr. IV-1</title>
          <description>Subjects received a single dose of ARALAST Fr. IV-1 60 mg/kg at 0.2 mL/kg/min</description>
        </group>
        <group group_id="E2">
          <title>ARALAST</title>
          <description>Subjects received a single dose of ARALAST 60 mg/kg at 0.2 mL/kg/min</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs vary per individual PI, but contain common elements. Baxter requires a review of results communications (e.g., for confidential information) ≥60 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (e.g., to allow for intellectual property protection).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Gelmont, MD, Global Medical Director, Head of Specialty Products TA, BioTherapeutics</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>david_gelmont@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

